Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

IQVIA HOLDINGS INC.

(IQV)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nyse
12/02/2021 12/03/2021 12/06/2021 12/07/2021 12/08/2021 Date
262.73(c) 261.68(c) 263.1(c) 270.3(c) 272.19(c) Last
1 115 763 864 153 766 295 1 086 087 888 419 Volume
+1.34% -0.40% +0.54% +2.74% +0.70% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 13 830 M - -
Net income 2021 922 M - -
Net Debt 2021 10 634 M - -
P/E ratio 2021 57,6x
Yield 2021 -
Sales 2022 14 905 M - -
Net income 2022 1 130 M - -
Net Debt 2022 9 674 M - -
P/E ratio 2022 46,6x
Yield 2022 -
Capitalization 51 999 M 51 999 M -
EV / Sales 2021 4,53x
EV / Sales 2022 4,14x
Nbr of Employees 77 000
Free-Float 74,2%
More Financials
Company
IQVIA Holdings Inc., formerly Quintiles IMS Holdings, Inc., provides integrated information and technology-enabled healthcare services. The Company operates through segments, including Commercial Solutions; Research & Development Solutions, and Integrated Engagement Services. The Commercial Solutions segment offerings include national information offerings, sub-national information offerings, technology solutions,... 
More about the company
Ratings of IQVIA Holdings Inc.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about IQVIA HOLDINGS INC.
08:09aGlobal Medicine Spending to Reach $1.8 Trillion in 2026, Including Spending on COVID-19..
BU
12/06Aslan Pharmaceuticals Working With Iqvia Biotech on Clinical Trials
MT
12/06ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
AQ
12/06ASLAN Pharmaceuticals and IQVIA Biotech Enter Into Strategic Collaboration
CI
12/02IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Service..
BU
12/02IQVIA Decentralized Trial Suite Launches Mobile Research Nursing and Phlebotomy Service..
CI
12/02INSIDER SELL : Iqvia Holdings
MT
12/01Teva Launches Epiduo Forte Gel's Generic Version in US
MT
12/01IQVIA Recognized as a Leader in BPO Solutions for Pharmaceutical Sales and Marketing
BU
11/19Amneal Pharmaceuticals Obtains FDA Approval for Difluprednate Ophthalmic Emulsion
MT
11/18IQVIA Launches New Grants/Funding Management Module for Its Orchestrated Customer Engag..
CI
11/18IQVIA Launches New Grants/Funding Management Module for Its Orchestrated Customer Engag..
BU
11/18Mizuho Securities Adjusts IQVIA Holdings' Price Target to $290 From $282, Reiterates Bu..
MT
11/18Piper Sandler Adjusts Price Target on IQVIA Holdings to $261 From $250, Maintains Neutr..
MT
11/17BofA Securities Adjusts IQVIA Holdings' Price Target to $320 From $290, Reiterates Buy ..
MT
More news
News in other languages on IQVIA HOLDINGS INC.
12/06Aslan Pharmaceuticals travaille avec Iqvia Biotech sur des essais cliniques
12/01Teva lance la version générique du gel Epiduo Forte aux États-Unis
11/25KOLINPHARMA : nuovi brevetti per 3 prodotti in Europa e Usa
11/19Amneal Pharmaceuticals obtient l'approbation de la FDA pour l'émulsion ophtalmique de d..
11/16IQVIA Holdings Inc. réaffirme ses prévisions de résultats
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Chart IQVIA HOLDINGS INC.
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | IQV | US46266C1053 | MarketScreener
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 272,19 $
Average target price 300,29 $
Spread / Average Target 10,3%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
W. Richard Staub President-Research & Development Solutions
Kevin C. Knightly President-Technology & Commercial Solutions
Sector and Competitors
1st jan.Capi. (M$)
IQVIA HOLDINGS INC.51.92%51 999
MODERNA, INC.171.27%114 904
LONZA GROUP AG30.52%59 816
SEAGEN INC.-14.61%27 346
CELLTRION, INC.-42.20%24 169
ICON PUBLIC LIMITED COMPANY42.78%22 661